Suppr超能文献

转移性结直肠癌——过去、进展与未来

Metastatic colorectal cancer-past, progress and future.

作者信息

Field Kathryn, Lipton Lara

机构信息

Department of Medical Oncology and Clinical Haematology, Western Hospital, Footscray 3011, Victoria, Australia.

出版信息

World J Gastroenterol. 2007 Jul 28;13(28):3806-15. doi: 10.3748/wjg.v13.i28.3806.

Abstract

The clinical management of metastatic (stage IV) colorectal cancer (CRC) is a common challenge faced by surgeons and physicians. The last decade has seen exciting developments in the management of CRC, with significant improvements in prognosis for patients diagnosed with stage IV disease. Treatment options have expanded from 5-fluorouracil alone to a range of pharmaceutical and interventional therapies, improving survival, and providing a cure in selected cases. Enhanced understanding of the biologic pathways most important in colorectal carcinogenesis has led to a new generation of drugs showing promise in advanced disease. It is hoped that in the near future the treatment paradigm of metastatic CRC will be analogous to that of a chronic illness, rather than a rapidly terminal condition. This overview discusses the epidemiology of advanced CRC and currently available therapeutic options including medical, surgical, ablative and novel modalities in the management of metastatic colorectal cancer.

摘要

转移性(IV期)结直肠癌(CRC)的临床管理是外科医生和内科医生共同面临的一项常见挑战。在过去十年中,CRC的管理取得了令人振奋的进展,IV期疾病患者的预后有了显著改善。治疗选择已从单纯的5-氟尿嘧啶扩展到一系列药物和介入治疗,提高了生存率,并在部分病例中实现了治愈。对结直肠癌发生过程中最重要的生物学途径的深入了解催生了新一代在晚期疾病中显示出前景的药物。人们希望在不久的将来,转移性CRC的治疗模式将类似于慢性病,而非快速致死性疾病。本综述讨论了晚期CRC的流行病学以及目前可用的治疗选择,包括转移性结直肠癌管理中的药物、手术、消融和新型治疗方式。

相似文献

1
Metastatic colorectal cancer-past, progress and future.
World J Gastroenterol. 2007 Jul 28;13(28):3806-15. doi: 10.3748/wjg.v13.i28.3806.
2
Novel agents in the treatment of metastatic colorectal cancer.
Cancer J. 2010 May-Jun;16(3):273-82. doi: 10.1097/PPO.0b013e3181e076c5.
3
Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.
Curr Drug Targets. 2018;19(15):1731-1737. doi: 10.2174/1389450119666180803122744.
4
BRAF in metastatic colorectal cancer: the future starts now.
Pharmacogenomics. 2015 Dec;16(18):2069-81. doi: 10.2217/pgs.15.140. Epub 2015 Nov 30.
5
Treatment advances in liver-limited metastatic colorectal cancer.
Clin Colorectal Cancer. 2011 Dec;10(4):258-65. doi: 10.1016/j.clcc.2011.06.008. Epub 2011 Aug 5.
7
Recent advances in the pharmacological treatment of colorectal cancer.
Expert Opin Investig Drugs. 2003 Mar;12(3):423-34. doi: 10.1517/13543784.12.3.423.
8
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer.
Biomed Res Int. 2016;2016:7590245. doi: 10.1155/2016/7590245. Epub 2016 Apr 5.
9
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.
JAMA. 2021 Feb 16;325(7):669-685. doi: 10.1001/jama.2021.0106.
10
Therapeutic advances in the management of metastatic colorectal cancer.
Expert Rev Anticancer Ther. 2001 Aug;1(2):236-46. doi: 10.1586/14737140.1.2.236.

引用本文的文献

1
Cluster-based human-in-the-loop strategy for improving machine learning-based circulating tumor cell detection in liquid biopsy.
Patterns (N Y). 2025 May 30;6(6):101285. doi: 10.1016/j.patter.2025.101285. eCollection 2025 Jun 13.
5
predicts prognosis and progression through cancer-related pathways in colorectal cancer.
Transl Cancer Res. 2022 Oct;11(10):3686-3697. doi: 10.21037/tcr-22-629.
6
Suppresses Metastatic Behavior by Inhibiting TGF-β-Mediated Epithelial-Mesenchymal Transition in 5-FU-Resistant HCT116 Cells.
Front Pharmacol. 2022 Jun 13;13:909331. doi: 10.3389/fphar.2022.909331. eCollection 2022.
7
Bacteria-Mediated Modulatory Strategies for Colorectal Cancer Treatment.
Biomedicines. 2022 Apr 1;10(4):832. doi: 10.3390/biomedicines10040832.
8
MiR-211-5p Inhibits the Biological Behaviors of Colorectal Cancer via SPARC-Related Growth Factor Pathways.
J Cancer. 2022 Mar 21;13(6):1895-1904. doi: 10.7150/jca.60269. eCollection 2022.
9
Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis.
Int J Colorectal Dis. 2022 May;37(5):1021-1027. doi: 10.1007/s00384-022-04144-4. Epub 2022 Apr 6.
10
Yin Yang 1 regulates ITGAV and ITGB1, contributing to improved prognosis of colorectal cancer.
Oncol Rep. 2022 May;47(5). doi: 10.3892/or.2022.8298. Epub 2022 Mar 10.

本文引用的文献

7
The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
Semin Oncol. 2005 Dec;32(6 Suppl 9):S55-8. doi: 10.1053/j.seminoncol.2005.04.020.
8
Drug-induced thrombotic microangiopathy.
Semin Thromb Hemost. 2005 Dec;31(6):681-90. doi: 10.1055/s-2005-925474.
10
Mortality and survival in breast and colorectal cancer.
Nat Clin Pract Oncol. 2005 Sep;2(9):424-5. doi: 10.1038/ncponc0288.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验